{
  "docId": "019de077-60e9-755b-a2a9-f474a1c234cc",
  "docSlug": "c7a8fd91214a0cf2ae7cadcb747376a3",
  "documentTitle": "MindMed | Investor Presentation Deck | 42 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 42,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Slide uses a list-based layout to present four distinct pillars of program progress.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-60e9-755b-a2a9-f474a1c234cc/8",
  "deckHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc",
  "deckJsonHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc.json",
  "deckAnchorHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.15,
        "x": 0.14,
        "y": 0.15
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00307496-804f-465f-9961-3e31b80b74b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.72,
        "x": 0.14,
        "y": 0.15
      },
      "kind": "list",
      "text": "Positive 12-Week Durability in Phase 2b Trial of GAD; Breakthrough Therapy Designation for GAD; Enhanced Product Profile of MM120 ODTs; Market Protection Strategies and IP Portfolio",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db93df4c-92e2-427e-9a52-a6886fcdb998",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.65,
        "x": 0.16,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Study MMED008 internal study documents and calculations. Source: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy. AUC: area under the curve; ODT: orally disintegrating tablet; PK: pharmacokinetic; SOC: standard of care",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5201379-8fed-4e7e-a0ad-1c296ca31b7d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.35,
        "x": 0.038,
        "y": 0.048
      },
      "kind": "title",
      "text": "Key Highlights of MM120 Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6c3ea18-242d-4872-b041-28eab81f645b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "51891bef-3a53-4876-81dc-4c57b7b04e96",
      "evidence": "list/bullet: Positive 12-Week Durability in Phase 2b Trial of GAD; Breakthrough Therapy Designation for GAD; Enhanced Product Profile of MM120 ODTs; Market Protection Strategies and IP Portfolio",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "79e83f52-47a1-4d4c-9661-d3ef941112d0",
      "evidence": "The slide uses a structured list of four key highlights to communicate program status.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "a218c047-f9dd-43b1-b607-76eb8fa90d3b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 7-14 discuss MM120 ODT Lysergide D-tartrate program",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}